Floatz logo

Antihemophilic Factor, Human Recombinant Residues 722-1672 Deleted

Hemophilia A

Explore 62 assets in Hemophilia A →
Floatz Rating
B60/100
Confidence
Indicative
v0.2
Sponsor
Octapharma
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05936580CT.gov
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
—Recruiting———
NCT04030052CT.gov
Emicizumab PUPs and Nuwiq ITI Study
—Withdrawn———
NCT04023019CT.gov
Treatment of Hemophilia A Patients With FVIII Inhibitors
—Recruiting———
NCT03344003CT.gov
Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq
—Terminated———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Hemophilia A

AssetSponsorPhaseRating
Antihemophilic Factor, Human Recombinant Residues 722-1672 Deleted (this asset)OctapharmaApprovedB · 60
Turoctocog AlfaNovo Nordisk A/SP4A
Eptacog Alfa (Activated)AryoGen Pharmed Co.P4A
Rurioctocog Alfa PegolTakedaP4BBB
Immunoglobulin G4 [230-Proline,De-449-Lysine], Anti-(Human Blood-Coagulation Factor Ix)(Human Clone 0365-0001-9985 ?4-Chain), Disulfide With Human Clone 0365-0001-9985 ?-Chain, (228?226?),(231?229?)-Bis(Disulfide) With Anti-(Human Blood-Coagulation Factor X) Immunoglobulin G4 [228-Proline,405-Leucine,409-Lysine,De-447-Lysine] (Human Clone 0365-0001-8174 ?4-Chain) Disulfide With Human Clone 0365-0001-8174 ?-ChainNovo Nordisk A/SP3BBB
N8-GPNovo Nordisk A/SP3BBB
bay94-9027BayerP4BBB
EmicizumabEmory UniversityP4BBB
FitusiranSanofiP4BBB

+36 more in the Hemophilia A cohort

Other indications for Antihemophilic Factor, Human Recombinant Residues 722-1672 Deleted

IndicationSponsorPhaseRating
Severe Hemophilia A—P4B · 62

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Antihemophilic Factor, Human Recombinant Residues 722-1672 Deleted in Hemophilia A. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/antihemophilic-factor-human-recombinant-residues-722-1672-deleted-hemophilia-a

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →